US 12,215,094 B2
Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
Eric A. Fromme, Flemington, NJ (US); and Kevin J. Klopfer, Flemington, NJ (US)
Assigned to Celgene Corporation, Summit, NJ (US)
Appl. No. 17/290,240
Filed by Celgene Corporation, Summit, NJ (US)
PCT Filed Nov. 1, 2019, PCT No. PCT/US2019/059379
§ 371(c)(1), (2) Date Apr. 30, 2021,
PCT Pub. No. WO2020/092894, PCT Pub. Date May 7, 2020.
Claims priority of provisional application 62/755,263, filed on Nov. 2, 2018.
Prior Publication US 2021/0403452 A1, Dec. 30, 2021
Int. Cl. C07D 401/14 (2006.01); A61K 45/06 (2006.01)
CPC C07D 401/14 (2013.01) [A61K 45/06 (2013.01); C07B 2200/13 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl] amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, wherein the crystalline form is characterized by an X-ray powder diffraction pattern presented in FIG. 1.